Skip to main content


Fig. 1 | Respiratory Research

Fig. 1

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Fig. 1

Proportion of participants free from acute exacerbations of chronic obstructive pulmonary disease (COPD). AZ, Azithromycin; PL, Placebo; HP, Helicobacter pylori. Pair-wise comparisons between each group showed significant differences in the time to first exacerbation between: The HP+/AZ group versus HP-/AZ group (11.2 months, 95% CI; 8.4–12.5+ vs 8.0 months, 95% CI; 6.7–9.7; p = 0.040); The HP+/AZ group versus the HP+/PL group (7.5 months, 95% CI; 4.9–8.8; p = 0.006); and The HP+/AZ group versus the HP-/PL group (5.7 months, 95% CI; 4.5–7.2; p = 0.001). There was a significant difference between the HP-/AZ and the HP-/PL groups (p = 0.020). The remaining pair-wise comparisons were not statistically significant

Back to article page